ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of cutaneous ...
WEST LAFAYETTE, Ind. — Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback